https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-01 / J. Immunother. 2007 Oct;30(7):749-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-01 / J. Immunother. 2007 Oct;30(7):749-612007-10-01 00:00:002019-02-15 09:16:55Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-01 / Int J Immunopathol Pharmacol 2007 Oct-Dec;20(4):707-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-01 / Int J Immunopathol Pharmacol 2007 Oct-Dec;20(4):707-172007-10-01 00:00:002019-02-15 09:16:53Apoptic renal carcinoma cells are better inducers of cross-presenting activity than their primary necrotic counterpart
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2007-10-01 / Cancer 2007 Oct;110(7):1469-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2007-10-01 / Cancer 2007 Oct;110(7):1469-772007-10-01 00:00:002019-02-15 08:38:10Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines
